For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service at certain sites in the UK for patients who meet the eligibility criteria.
Here you can find out more about BRCA testing, what the AstraZeneca
Tumour BRCA testing service
Who is eligible for this service?
Patients who are eligible for this service are those that have ovarian cancer and either a known negative germline BRCA mutation status or an unknown germline BRCA mutation status. Patients must have received at least two prior lines of treatment (i.e.